BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21070475)

  • 1. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
    Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
    Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
    Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
    J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
    Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
    Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
    Li F; Jiang S; Zu Y; Lee DY; Li Z
    J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vascular endothelial growth factor 121 (VEGF(121))-based dual PET/optical probe for in vivo imaging of VEGF receptor expression.
    Kang CM; Koo HJ; Lee KC; Choe YS; Choi JY; Lee KH; Kim BT
    Biomaterials; 2013 Sep; 34(28):6839-45. PubMed ID: 23787114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
    Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
    J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B.
    Zhou B; Wang H; Liu R; Wang M; Deng H; Giglio BC; Gill PS; Shan H; Li Z
    Mol Pharm; 2015 Oct; 12(10):3527-34. PubMed ID: 26288060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P; Knight LC; Welch MJ
    Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
    Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K
    Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
    Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.
    Marquez BV; Ikotun OF; Parry JJ; Rogers BE; Meares CF; Lapi SE
    J Nucl Med; 2014 Jun; 55(6):1029-34. PubMed ID: 24732153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET of vascular endothelial growth factor receptor expression.
    Cai W; Chen K; Mohamedali KA; Cao Q; Gambhir SS; Rosenblum MG; Chen X
    J Nucl Med; 2006 Dec; 47(12):2048-56. PubMed ID: 17138749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody.
    Stollman TH; Scheer MG; Leenders WP; Verrijp KC; Soede AC; Oyen WJ; Ruers TJ; Boerman OC
    Int J Cancer; 2008 May; 122(10):2310-4. PubMed ID: 18240146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
    Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature.
    Chen K; Sun X; Niu G; Ma Y; Yap LP; Hui X; Wu K; Fan D; Conti PS; Chen X
    Mol Imaging Biol; 2012 Feb; 14(1):96-105. PubMed ID: 21360213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
    Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
    Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.